Mar 25, 2020
Innovaderm is following Health Canada, regional authorities, and Centers for Disease Control (CDC) guidance. Following the latest announcement by the Quebec Government requesting all non-essential businesses to close their offices to facilitate the enforcement of social distancing until April 13, 2020, our headquarters offices are closed since March 24th, 2020, without major impact on our services. There will be no interruption in Innovaderm CRO services. All employees will work remotely during this period. Public transit, air and rail travel will be discouraged in regions with known outbreaks.
Innovaderm will continue to review our business continuity plan and adjust as needed. Further updates and information about Innovaderm’s response to COVID-19 will be shared on this webpage.
For COVID-19 criteria, visit the following websites:
NEW !! EMA Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf
New !! Health Canada:
Notice to clinical trial sponsors
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic
https://www.fda.gov/media/136238/download
Health Canada:
http://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/canadas-reponse.html
CDC:
http://www.cdc.gov/coronavirus/2019-ncov/index.html
WHO:
http://www.who.int/emergencies/diseases/novel-coronavirus-2019
